EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EDAP TMS reports Q1 revenue growth and FDA breakthrough designation

EDAP TMS reported solid revenue growth in Q1 2024, driven by strong international placements and advancements in Focal One technology. While facing financial challenges, the company is strategically positioned to benefit from the expanding HIFU market and upcoming regulatory milestones. Opportunities lie in market expansion, new study data releases, and continued engagement with regulatory bodies.

EDAP TMS reports strong Q2 earnings, poised for market expansion

EDAP TMS delivered robust performance in Q2 2024, driven by revenue growth and advancements in key medical programs.
While facing challenges in profitability and expenses, the company is strategically positioned to capitalize on market opportunities.
Investments in research, management, and clinical trials signal a proactive approach towards sustainable growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

 Generated strongest total revenue quarter of 2020

EDAP Reports Third Quarter 2020 Results and Provides Operational Update

LYON, France, November 17, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive distribution agreement with AB Medica, a leading distribution of medical technologies across Italy.

EDAP Announces Exclusive Distribution Agreement with Leading Italian Medical Device Distributor AB Medica

LYON, France, November 10, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the Jefferies Virtual London Healthcare Conference, which is being held November 17-19, 2020. 

EDAP Announces Presentation at the Jefferies Virtual London Healthcare Conference

Company to host conference call and webcast on Thursday, November 19 at 8:30 am EDT

EDAP TMS SA to Announce Third Quarter 2020 Financial Results on November 18, 2020

Knifeless Surgery: Prospects And Competition For EDAP

As of late, it has definitely been a great time to be an investor in EDAP TMS.

EDAP TMS' Shares March Higher, Can It Continue?

The company offers an innovative device that produces non-invasive HIFA treatment for prostate cancer with other applications to follow.

EDAP Set For Long-Term Growth

Call to be Held Tuesday, September 22nd @ 8am Eastern Time

EDAP Hosting Key Opinion Leader Call on Focal One® and ExactVu™

As of late, it has definitely been a great time to be an investor EDAP TMS.

EDAP's Shares March Higher, Can It Continue?

LYON, France, September 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held September 14-15, 2020. 

EDAP Announces Presentation at the HC Wainwright Virtual 22nd Annual Global Investment Conference

EDAP Announces First Patients Treated in Phase 2 Study of Focal One for the Treatment of Deep Invasive Endometriosis

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q2 2020 Results - Earnings Call Transcript

LYON, France, August 26, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the second quarter of 2020 and provided an update on strategic and operational developments. 

EDAP Reports Second Quarter 2020 Results and Provides Operational Update

LYON, France, August 25, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company has received approval from French health authorities to initiate a Phase II multicenter clinical trial evaluating its Focal One® HIFU to treat deep rectal endometriosis.

EDAP Announces Approval for Phase II Study Evaluating High Intensity Focused Ultrasound (HIFU) for Deep Invasive Endometriosis 

Company to host conference call and webcast on Thursday, August 27 at 8:30 am EDT

EDAP TMS SA to Announce Second Quarter 2020 Financial Results on August 26, 2020

 Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015.

EDAP Announces Two Publications Highlighting Favorable HIFU Focal Therapy Outcomes in Journal of Urology

EDAP TMS (EDAP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

EDAP TMS (EDAP) Catches Eye: Stock Jumps 7.4%

LYON, France, July 15, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent sales successes that occurred during the second quarter and early third quarter.

EDAP Announces Recent Focal One Sales Successes

 LYON, France, June 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announced today that veteran medical technology executive Marie Meynadier has been elected to its Board of Directors, effective June 30, 2020, following a vote by the company’s shareholders. Ms. Meynadier has more than 20 years of experience in medical technology operations and leadership and most recently served as Chief Executive Officer of EOS Imaging.

EDAP Appoints Medical Technology Executive Marie Meynadier to its Board of Directors

LYON, France, May 28, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announced today the appointment of Frank Van Hyfte as Vice President of Global Sales and Marketing. Mr. Van Hyfte joins EDAP from Exact Imaging, where he most recently served as Executive Vice-President of Worldwide Sales and Marketing. On May 12, 2020, EDAP announced that the Company had entered into an exclusive worldwide distribution agreement with Exact Imaging to integrate Exact’s ExactVu™ and other micro ultrasound diagnostic products in EDAP’s offering in the management of prostate cancer as a stand-alone range or in combination with its Focal One high intensity focused ultrasound (HIFU) treatment technology.

EDAP Appoints Frank Van Hyfte as Vice President of Global Sales and Marketing

EDAP Shares Are Still A Steal, But The Pandemic Could Be A Wrench

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q1 2020 Results - Earnings Call Transcript

LYON, France, May 13, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the first quarter of 2020 and provided an update on strategic and operational developments. 

EDAP Reports First Quarter 2020 Results and Provides Operational Update

LYON, France, May 12, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive worldwide distribution agreement with Exact Imaging, a developer of high resolution micro-ultrasound imaging technologies. Under the terms of the agreement, EDAP will market Exact Imaging’s micro-ultrasound diagnostic devices alongside its Focal One high intensity focused ultrasound (HIFU) treatment solution. The combination of these technologies represents the most complete end-to-end solution, from diagnosis through treatment, available to urologists today.     

EDAP ANNOUNCES EXCLUSIVE WORLDWIDE DISTRIBUTION RIGHTS TO EXACT IMAGING’S MICRO-ULTRASOUND TECHNOLOGIES

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q4 2019 Results - Earnings Call Transcript

News for EDAP TMS Stock (EDAP)